ArticleChinese medicine2026
Licoisoflavone A potentiates oxaliplatin efficacy in colorectal cancer by dual targeting arginine metabolism of tumor microenvironment and cancer cells.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) remains a leading cause of cancer-related mortality, with resistance to oxaliplatin (Oxa) and its associated side effects posing major therapeutic challenges. Natural flavonoids have shown potential in the prevention and treatment of CRC. PURPOSE: This study aimed to investigate whether combining Oxa with the bioactive flavonoid licoisoflavone A (LA) derived from Glycyrrhiza species could exert enhanced antitumor effects against CRC and to explore the underlying mechanisms.
methodsA CT26 tumor-bearing mouse model was established to evaluate the therapeutic efficacy of Oxa in combination with LA in vivo. Mass spectrometry-based proteomics and metabolomics analyses were performed to identify differentially expressed proteins and metabolites between the Oxa group and the Oxa plus LA group. Differential expressed proteins and associated pathways were subsequently validated in HCT116 cells, SW480 cells, and patient-derived organoids. Furthermore, two complex organoid models-an organoid-lymphocyte co-culture system and an air-liquid interface organoid system-were developed to investigate the underlying mechanisms. Flow cytometry and Western blot analyses were employed in both in vitro and in vivo settings.
resultsThe combination of LA and Oxa significantly inhibited tumor growth in CT26 tumor-bearing mice. Arginine metabolism was significantly reduced following LA treatment. Arginase-1 (ARG1) was identified as a potential target of LA. LA significantly downregulated ARG1 expression, which was associated with an increased proportion of CD8⁺ T cells and reduced expression of CD69⁺ and PD-1, suggesting a potential alleviation of T cell exhaustion-related features. Moreover, LA inhibited CRC cell proliferation by suppressing ARG1-mediated activation of the PI3K/Akt/mTOR signaling pathway.
conclusionsLA is a natural flavonoid that targets arginine metabolism and enhances the therapeutic efficacy of Oxa in CRC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.